Overview

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.

Phase:

Phase 2

Details

Lead Sponsor:

Scilex Pharmaceuticals, Inc.

Collaborator:

Worldwide Clinical Trials